Portal Biotechnologies Raises $9M as Cell Engineering Moves From Research Tool to Infrastructure

Portal Biotechnologies, a Watertown, Massachusetts-based cell engineering and drug discovery platform company, has raised $9M in an oversubscribed financing round led by NFX, with participation from IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures. The company is led by Armon Sharei, Ph.D., Founder and CEO, and Alec Barclay, Co-Founder and COO, and is building a mechanoporation-based intracellular delivery platform designed to move RNA, gene editors, probes, and other biological cargo into difficult-to-engineer cells.

The funding will support expansion across drug discovery, AI data generation, and cell therapy manufacturing, three markets increasingly dependent on scalable cell engineering infrastructure. The broader significance extends beyond a single financing round, as investors continue directing capital toward foundational technologies that enable biological innovation rather than solely funding applications built on top of them.

What Happened

Funding announcements often arrive wrapped in familiar language: vision, disruption, transformation. The challenge is separating narrative from signal. Portal Biotechnologies offers a clearer signal than most. The company announced an oversubscribed $9M financing round led by NFX, joined by existing investors IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures. The capital will be used to expand Portal's platform across drug discovery, AI data generation, and cell therapy manufacturing.

At its core, Portal is attacking a problem that has quietly frustrated researchers and developers for years. Modern biology has become remarkably good at creating new molecules, editing genes, and designing sophisticated cellular therapies, but getting those tools efficiently inside cells remains a separate challenge altogether. That challenge has become increasingly important as pharmaceutical companies pursue more complex biological therapies and as AI-driven drug discovery startups generate larger volumes of experimental candidates requiring validation. Portal's mechanoporation technology is designed to address that delivery problem directly by building the infrastructure layer that allows cell engineering to happen more efficiently and at greater scale.

Why This Matters

Every major technology wave eventually encounters an invisible constraint. Cloud computing needed scalable data infrastructure. Artificial intelligence needed computing power and training data. Cell engineering needs reliable delivery. Portal Biotechnologies is positioning itself in that constraint layer by enabling researchers to introduce biological cargo into cells through a proprietary mechanoporation platform.

Mechanoporation competes against established delivery methods such as electroporation, viral vectors, and chemical transfection, each with tradeoffs around scalability, efficiency, and cell viability. While the underlying science is highly technical, the business implication is straightforward: improving delivery efficiency can accelerate research, improve manufacturing workflows, and expand the practical utility of advanced cellular therapies. Investors increasingly understand this dynamic because the most valuable opportunities in emerging markets are often found in the systems that make products possible rather than the products themselves. Portal's financing suggests investors see delivery infrastructure becoming a strategic category rather than a technical afterthought.

Market Context

Timing matters in venture capital. Portal's financing arrives as pharmaceutical companies, biotechnology firms, and research institutions continue investing heavily in cell engineering, gene editing, and AI-assisted drug discovery. AI can now generate molecular hypotheses at unprecedented speed, drug discovery platforms can identify promising targets faster than ever, and gene editing technologies continue advancing. Yet biological validation remains stubbornly physical because cells still need to be modified, experiments still need to be conducted, and manufacturing still needs to scale.

This creates demand for technologies that improve throughput, consistency, and reproducibility. Portal reports more than 100 customers and customer sites along with more than 50 paid partnerships since beginning operations in 2023, suggesting the company has moved beyond theoretical interest and into practical adoption. Portal Biotechnologies also joins a growing cluster of Boston and Cambridge biotechnology companies building foundational infrastructure for next-generation therapeutics, reinforcing the region's position as one of the world's leading biotech ecosystems. Adoption remains one of the strongest forms of validation in biotechnology because researchers rarely change workflows without a compelling reason.

Competitive Landscape

The intracellular delivery market includes established approaches such as viral vectors, electroporation systems, and chemical transfection methods. Portal is pursuing a different path through mechanoporation while positioning its platform as a versatile delivery system capable of supporting drug discovery workflows, cell engineering applications, and cell therapy manufacturing.

Its product portfolio includes Gateway, Galaxy, MilliBooster, and Galaxy-i, reflecting a strategy that extends beyond a single instrument or research tool. This approach resembles a broader trend emerging across biotech infrastructure startups, where the winners increasingly become platforms rather than products. Platforms create recurring usage, generate data, and become embedded inside customer workflows. Those characteristics tend to attract investor attention because they create long-term strategic value.

What This Signals

Another important signal comes from outside venture capital. Portal previously secured an $8M DARPA contract tied to the DARPA Red Blood Cell Factory Program, an initiative focused on advancing portable red blood cell engineering capabilities at the point of care. Government-backed programs like DARPA rarely operate as popularity contests. They exist to identify technologies capable of solving difficult technical challenges.

For investors, that kind of validation matters. For customers, it matters even more. The combination of commercial adoption, venture funding, and government support creates a stronger signal than any one milestone in isolation. Viewed together, those milestones suggest Portal is building technology that multiple stakeholder groups consider valuable and worthy of long-term investment.

The Bigger Industry Shift

The biotechnology industry is entering a new phase. The previous decade rewarded discovery. The next decade may reward execution. Generating biological insights has become faster through advances in computation, automation, and AI, but translating those insights into scalable products remains the harder challenge.

That shift elevates the importance of infrastructure companies. Portal Biotechnologies represents a broader category of startups building the connective tissue between scientific possibility and commercial reality. Investors are increasingly funding those layers because breakthroughs do not create value on their own; systems that make breakthroughs usable create value. As Portal expands across drug discovery, AI data generation, and cell therapy manufacturing, the company is effectively making a bet on where biology is heading next, and the market appears increasingly willing to make that bet alongside them.